Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
HOME > BUSINESS
BUSINESS
- Astellas, GSK, 2 Other Firms Log 10%-Plus Drop in Workforce: Jiho Poll
April 11, 2022
- CMS Decision De-Facto Denial of All Medicare Patient Access to Aduhelm: Biogen
April 11, 2022
- Kowa Appeals to Intellectual Property High Court in Livalo Damage Suit
April 8, 2022
- Novartis’ Japan Sales Inch Down to 320.5 Billion Yen, Revolade Rises to Best Seller
April 8, 2022
- Meiji Begins US/Canada PII Study of PDE4 Inhibitor for Plaque Psoriasis
April 8, 2022
- Japan Ethical Drug Sales Up 3.5% in February: Crecon
April 8, 2022
- Japan Pharma Sales Tick Up 2.9% in FY2021: Encise
April 8, 2022
- New Grad Hiring Down 4.4% in Spring 2022, Downtrend for Sales Reps Continues: Poll
April 7, 2022
- Jardiance Now Allowed for Use in HFpEF Patients: Label Update
April 7, 2022
- Detailing Activities via Webinars Chalk Up Double-Digit Growth in February: Intage
April 7, 2022
- Ratio of Blood-Based Gene Profiling Test at 1.4%; Cervical Cancer Most Frequently Tested: Survey
April 7, 2022
- Jardiance, Ofev Drive Up Boehringer’s Japan Sales in 2021
April 6, 2022
- Teijin, Iktos Ink Pact for AI-Based Discovery of Small Molecule Drugs
April 6, 2022
- Lundbeck Launches Japan-US PII for Multiple System Atrophy Treatment
April 6, 2022
- Pfizer Tops 2021 Global Pharma Ranking on Vaccine Boon: Jiho Tally
April 6, 2022
- Fujifilm Completes Acquisition of Atara’s US Cell Therapy Site
April 6, 2022
- Shionogi-Led Continuous Manufacturing JV Now Up and Running
April 4, 2022
- 400 Kobayashi Kako Staffers Move to Trust Pharmatech
April 4, 2022
- Ukraine War Disrupts Ryzodeg Supplies to Japan: Novo
April 4, 2022
- Sumitomo Dainippon Renamed “Sumitomo Pharma”
April 4, 2022
ページ
Japan is opening a new chapter in sleep medicine. The recent decision to allow medical institutions to advertise “sleep disorders”…
Let’s face it: in today’s world, changing jobs is a normal part of a successful career. But if it’s so normal, why does it feel so hard? For many people, the idea of leaving their current role brings a heavy…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…